Ironwood secures FDA fast track designation for heart drug praliciguat

Ironwood secures FDA fast track designation for heart drug praliciguat

Source: 
Pharmaceutical Business Review
snippet: 

Ironwood Pharmaceuticals has secured fast track designation from the US Food and Drug Administration (FDA) for praliciguat (IW-1973) for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).